Find policies, billing codes, payers, states, and providers

CPT 81413: Genomic Panel for Cardiac Ion Channelopathies

CPT code 81413 represents a laboratory-performed genomic sequencing panel that analyzes at least 10 genes linked to cardiac ion channelopathies — genetic disorders that affect ion channel proteins and can alter cardiac electrical conduction. Nationally, this code captures advanced molecular diagnostic testing used in cardiology, electrophysiology, and genetic counseling to inform diagnosis, risk stratification, and family screening.

Key payers in coverage analyses include Aetna, Blue Cross Blue Shield, Cigna Health, United Healthcare, and Medicare. Readers will find a concise overview of the clinical context for cardiac channelopathy panels, the laboratory service model (technical sequencing and analysis), and how this code relates to other molecular oncology and pathology services. The publication summarizes typical sites of service, associated clinical indications, and related laboratory procedures commonly billed alongside panel testing.

The report provides practical benchmarks and policy-relevant information: coverage and utilization patterns among major payers, coding relationships with other molecular and histopathology services, and common billing scenarios where 81413 applies. The intent is to inform coding, billing, and clinical stakeholders about the role of this genomic panel in patient care and how it is positioned within the broader molecular diagnostics landscape.

Customize your policy alerts

Sign up for cpt 81413 policy alerts

Get alerted when payer policies referencing 81413 are released or updated.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Billing Code Overview

CPT code 81413 describes a genomic sequence analysis panel that evaluates a patient specimen for genetic sequences across at least 10 genes associated with cardiac ion channelopathies, disorders of membrane proteins that influence the heart's electrical activity. The procedure encompasses the full laboratory technical workflow for sequencing and analyzing the specified gene panel.

Service type: Genomic sequencing panel — laboratory technical component

Typical site of service: Clinical molecular pathology or molecular diagnostics laboratory, often performed on specimens collected in outpatient or inpatient settings and processed in a reference or hospital-based molecular lab.

National Reimbursement Benchmarks

Commercial rates for CPT 81413 cluster around BUCA’s average commercial benchmark of $613.30, with substantial variation among national payers. Blue Cross Blue Shield shows the highest dispersion and upper-end rates, with a broad spread between $472.70 (P25) and $776.20 (P75) and a max outlier at $2,346.10, while Cigna and UnitedHealth Group also present high ceilings of $2,654.00 and $2,165.30 respectively. Aetna’s central tendency is lower, with a mean of $417.90 and median of $456.20, sitting nearer BUCA’s midpoint than the highest-pay insurers.

Measure of interquartile dispersion (P75 minus P25) highlights which payers are tightest or widest: Aetna’s range is $258.60, UnitedHealth Group’s is $318.30, BUCA’s is $382.20, Blue Cross Blue Shield’s is $289.50, and Cigna’s is $494.50. Cigna exhibits the widest IQR at $494.50, indicating the greatest mid-market variability, while Aetna is the tightest at $258.60, suggesting the most concentrated middle distribution among these commercial payers.

Find policies, billing codes, payers, states, and providers

CPT 81413: Genomic Panel for Cardiac Ion Channelopathies

Customize your policy alerts

Sign up for cpt 81413 policy alerts

Get alerted when payer policies referencing 81413 are released or updated.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Billing Code Overview

Service type: Genomic sequencing panel — laboratory technical component

National Reimbursement Benchmarks

National Payer Mean Reimbursement Rates

Clinical & Coding Specifications

Clinical Context

A 52-year-old patient with a family history of sudden cardiac death presents with palpitations and syncope. The cardiology team orders a hereditary cardiac arrhythmia panel to evaluate for cardiac ion channelopathies. A blood sample is collected in clinic and sent to an accredited molecular pathology laboratory. The laboratory accessioning staff logs the specimen; a molecular technologist extracts DNA and performs next-generation sequencing targeting the panel of genes (at least 10) implicated in ion channel disorders. A laboratory analyst performs the technical steps of the genomic sequence analysis, including library preparation, sequencing, primary data processing, and generation of variant calls. A molecular pathologist or laboratory director reviews technical quality metrics and signs out a clinical report indicating pathogenic, likely pathogenic, or variants of uncertain significance with interpretation tied to the patient’s clinical presentation. Results are routed back to the ordering cardiologist for correlation with ECG findings and family counseling. Billing for the technical component and molecular analysis uses 81413 for the genomic sequence analysis panel targeting cardiac ion channelopathy genes.

Coding Specifications

Modifier	Description	When to Use
`26`	Professional component	Use when billing only the professional interpretation by the laboratory director or pathologist separate from the technical sequencing work.

TC | Technical component | Use when billing only the technical sequencing and analytic work performed by the laboratory (sequencer, technician time, reagents).

90 | Reference (outside) laboratory | Use when the service is performed by an outside/reference laboratory and the ordering facility bills for the test performed externally.

59 | Distinct procedural service | Use when another distinct laboratory procedure is performed on the same day that is not usually bundled with the panel and meets modifier criteria.

62 | Two surgeons (shared responsibility) | Rare for this procedure; applicable if two qualified practitioners in a single group share professional sign-out responsibilities.

82 | Assistant surgeon (when a qualified resident is unavailable) | Rarely applicable; used only if an assistant surgeon role is legitimately part of a clinical workflow associated with procedure oversight.

52 | Reduced services | Use when the full genomic panel was not completed or sequencing yield was incomplete and the service provided is reduced in scope.

53 | Discontinued procedure | Use if testing was initiated but aborted for technical reasons prior to completion and not billable as full service.

76 | Repeat procedure by same provider | Data not available in the input.

77 | Repeat procedure by another provider | Data not available in the input.

90 is already listed above; other listed modifiers not enumerated here are omitted per relevance.

Taxonomy Code	Specialty	Notes
`207ZP0102X`	Pathology	Laboratories performing molecular diagnostic testing and signing out technical or consultative components.

207L00000X | Anatomic Pathology | Anatomic pathologists may oversee tissue-based testing and correlate molecular results with specimen pathology.

207RI0200X | Internal Medicine - Medical Oncology | Medical oncologists may order somatic tumor panels; in germline cardiac panels they are less common but involved when cancer predisposition intersects with cardiac genetics.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`C34.90`	Malignant neoplasm of unspecified part of unspecified bronchus or lung	Somatic tumor panels may be ordered when lung cancer is suspected; molecular testing can guide targeted therapy decisions and may be billed alongside tumor panels.

C50.919 | Malignant neoplasm of unspecified site of unspecified female breast | Breast cancers often undergo molecular and IHC testing; while 81413 is a germline cardiac panel, related molecular workflows occur in oncology laboratories.

C18.9 | Malignant neoplasm of colon, unspecified | Colorectal tumors undergo molecular profiling; relationship is via laboratory workflows and possible concurrent testing.

C61 | Malignant neoplasm of prostate | Prostate cancer specimens may be subject to molecular or tissue-based testing in the same laboratory environment.

C25.9 | Malignant neoplasm of pancreas, unspecified | Pancreatic tumors often require molecular characterization; listed here for clinical workflow overlap with molecular diagnostic laboratories.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`81445`	Targeted genomic sequence analysis panel, solid organ neoplasm, DNA analysis, 5-50 genes	May be used for tumor-focused panels; related when targeted oncology panels are performed instead of or in addition to germline cardiac panels.

88342 | Immunohistochemistry, per specimen; initial single antibody stain procedure | Used when immunohistochemical stains are performed on tissue specimens that accompany molecular testing in a diagnostic workup.

88341 | Immunohistochemistry, per specimen; each additional single antibody stain procedure | Billed for additional IHC stains performed on the same specimen alongside molecular analysis.

88360 | Morphometric analysis, tumor immunohistochemistry (e.g., HER-2/neu), quantitative or semiquantitative | Applied when quantitative IHC morphometry complements molecular testing in tumor characterization.

Related Codes

CPT-81410-GENOMIC-PANEL-AORTIC-DISEASE

CPT 81410: Genomic Sequencing Panel for Aortic Dysfunction

CPT-81411-GENETIC-DUPLICATION-DELETION-PANEL-AORTIC-DISEASE

CPT 81411: Genetic Duplication/Deletion Panel for Aortic Disease

CPT-81412-ASHKENAZI-JEWISH-GENOMIC-SEQUENCE-PANEL

CPT 81412: Ashkenazi Jewish Multi-Gene Genomic Sequence Panel

CPT-81414-CARDIAC-ION-CHANNELOPATHY-CNV-PANEL

CPT 81414: Cardiac Ion Channelopathy CNV Panel

CPT-81415-EXOME-SEQUENCE-ANALYSIS-UNEXPLAINED-DISORDER

CPT 81415: Exome Sequence Analysis for Unexplained Disorders

CPT-81416-FAMILIAL-EXOME-SEQUENCE-ANALYSIS

CPT 81416: Familial Exome Sequence Analysis for Diagnostic Comparison

CPT-81417-EXOME-SEQUENCE-REEVALUATION

CPT 81417: Reanalysis of Existing Exome Sequence

CPT-81418-PHARMACOGENOMIC-MULTIGENE-DRUG-METABOLISM-PANEL

CPT 81418: Pharmacogenomic Multigene Drug-Metabolism Panel

CPT-81419-GENOMIC-SEQUENCE-PANEL-EPILEPSY

CPT 81419: Genomic Sequence Analysis Panel for Epilepsy

CPT-81420-NIPS-FETAL-ANEUPLOIDY-SEQUENCING-PANEL

CPT 81420: Noninvasive Prenatal Sequencing Panel for Chromosomes 13, 18, 21

Showing 1–10 of 43

Frequently Asked Questions

References

1.CPT® Codes and Descriptions. AAPC. Retrieved Jul 29, 2026.
2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Jul 29, 2026.
3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Jul 29, 2026.

Published by

Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Clinical & Coding Specifications

Clinical Context

Coding Specifications

Modifier	Description	When to Use
`26`	Professional component	Use when billing only the professional interpretation by the laboratory director or pathologist separate from the technical sequencing work.